Selvin Jacob, MD
Pulmonary Disease · Boston, MANPI 1073040333
Payments from drug & device makers
Across 20 payments — averaging $88.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$433
- Sanofi$284
- United Therapeutics Corporation$250
- Regeneron Healthcare Solutions, Inc.$216
- Genentech USA, Inc.$133
- Amarin Pharma, Inc.$121
- plus $340 from 4 others
What the payments were for
- Food & beverage$1,777100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $433 |
| Sanofi | 3 | $284 |
| United Therapeutics Corporation | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 2 | $216 |
| Genentech USA, Inc. | 1 | $133 |
| Amarin Pharma, Inc. | 1 | $121 |
| Pfizer | 1 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $95 |
| Actelion Pharmaceuticals US, Inc. | 3 | $94 |
| AbbVie | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,777 in reported general payments places this provider in the 65th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $283,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,328 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $9,978 |
| Tacrolimus | 35 | $3,282 |
| Mycophenolate Mofetil | 18 | $2,928 |
| Ventolin HfaAlbuterol Sulfate | 11 | $740 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $609 |
| Azelastine Hcl | 21 | $386 |
| Pantoprazole Sodium | 25 | $255 |
| Prednisone | 47 | $182 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 38 | $158 |
| Gabapentin | 19 | $145 |
| Famotidine | 20 | $128 |
| Fluticasone Propionate | 13 | $98 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boston
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Gary HunninghakeBoston$1.5M
- Peter LacameraBoston$1.3M
- Barry SheaBoston$1M
- Isabel NeuringerBoston$817K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.